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Immunotherapies are an emerging strategy for treatment of solid tumors. Improved 
understanding of the mechanisms employed by cytotoxic T lymphocytes (CTLs) to 
control tumors will aid in the development of immunotherapies. CTLs can directly kill 
tumor cells in a contact-dependent manner or may exert indirect effects on tumor cells 
via secretion of cytokines. Here we aim to quantify the importance of these mechanisms 
in murine thymoma EL4/EG7 cells. We developed an agent-based model (ABM) and an 
ordinary differential equation (ODE) model of tumor regression after adoptive transfer of 
a population of CTLs. Models were parameterized based on in vivo measurements of 
CTL infiltration and killing rates applied to EL4/EG7 tumors and OTI T cells. We 
quantified whether infiltrating CTLs are capable of controlling tumors through only direct, 
contact-dependent killing. Both models agreed that the low measured killing rate of 
CTLs in vivo was insufficient to cause tumor regression. In our ABM we also simulated 
CTL production of the cytokine interferon gamma (IFNγ) in order to explore how an 
antiproliferative effect of IFNγ might aid CTLs in tumor control. In this model IFNγ 
substantially reduced tumor growth compared to direct killing alone. Collectively these 
data demonstrate that contact-dependent killing is insufficient for EL4 regression in vivo 
and highlight the potential importance of cytokine-induced antiproliferative effects in T 
cell-mediated tumor control. 
 
Significance: Computational modelling highlights the importance of cytokine-induced 
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In the last decade, immunotherapies for cancer have moved into the mainstream of clinical 
oncology. Antibodies targeting immune checkpoints have been particularly successful, offering 
significant advantages over chemotherapy in a range of advanced metastatic, relapsed, and 
refractory solid tumors. CTLA-4, PD-1, and PD-L1 inhibitors are now approved in melanoma, 
non-small-cell lung cancer, renal cell carcinoma, urothelial carcinoma, merkel cell carcinoma, 
and some colon cancers(1). Another promising immunotherapeutic approach has been the 
transfer of large numbers of cytotoxic T lymphocytes (CTLs). The transferred cells can be either 
autologously derived tumor infiltrating lymphocytes (TILs), or engineered with a chimeric antigen 
receptor (CAR) for tumor specificity. 2017 saw the first FDA approvals of CAR T cells for 
treatment of B cell malignancies(2). The potential of adoptive transfer therapies for solid tumors 
has been highlighted in trials using TILs against melanoma(3–5), or CAR T cells against a range 
of solid tumors(6–8). However, these promising early results have so far failed to transfer into 
the clinic.  
 
Many attempts are being made to improve the efficacy and broaden the scope of cancer 
immunotherapies. For example, immunotherapies can have a synergistic effect when applied 
together with other immunotherapies(9,10), or with traditional treatments such as radiotherapy 
and chemotherapy(11,12). Optimal treatment scheduling and dosages are yet to be determined. 
Given the danger of life threatening immune related adverse events following immunotherapy as 
well as the high costs involved, biomarkers to indicate which patients are likely to benefit from 
these treatments will be highly valuable. In particular, the immunosuppressive microenvironment 
which often characterises solid tumors represents a significant hurdle to the expansion and 
improvement of immunotherapies. Given the complex nature of the various mechanisms of 
interaction involved in determining the success of immunotherapies, a quantitative 
understanding of the contribution of these various mechanisms will be highly beneficial for the 
rational design and optimisation of cancer immunotherapies. 
 
One highly relevant topic requiring greater quantitative insight regards the mechanisms 
employed by CTLs to control tumors in vivo. Indeed, these cells are key players in anti-tumor 
immune responses, which they are thought to achieve through being extremely efficient killers. 
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This reputation has primarily been established by in vitro studies showing evidence of serial or 
simultaneous killing of several target cells in a short time frame(13,14). Killing by CTLs is 
usually considered to be ‘direct’, i.e., contact dependent, and mediated by either perforin and 
granzymes, or FAS-L. Several studies have suggested that direct lysis of tumor cells by CTLs is 
extremely important in tumor control(15–18). However, the reported killing rates of CTLs in vivo 
are typically low(19) and it is not clear whether these rates are indeed sufficient for control of 
tumors. Several studies have highlighted the importance of ‘indirect’ effects of cytokine 
signalling by activated T cells in the control of tumors, in particular IFNγ (20,21). IFNγ may 
control tumors by exertion of an antiproliferative effect(22), sensitization of tumor cells to FAS-L 
mediated death(23), recruitment of effector cells of the innate immune system(24), and by 
causing widespread necrosis of tumor cells along with tumor vasculature destruction(25).  
 
In the current study we quantitatively compare the importance of direct, contact dependent 
killing, with indirect cytokine mediated tumor control, based on published experiments in which 
EL4/EG7 tumor cells were infused into mice(18). We chose to focus on the EL4 tumor cell line 
which, along with its transformed Ova antigen expressing derivative EG7, has been widely used 
to explore the anti-tumor activities of CTLs in an in vivo setting(18,21,26–29). Using these cell 
lines, evidence has emerged supporting an important role for IFNγ in tumor control by CTLs yet 
a negligible role for direct killing, along with apparently contradictory evidence suggesting an 
important role for direct killing. Hollenbaugh et al.(30) transferred perforin and FasL deficient T 
cells into EG7 tumor bearing mice, and these deficient T cells were able to control tumors 
almost as well as their wild type counterparts. However, IFNγ deficient T cells displayed a 
marked reduction in tumor control, suggesting that IFNγ rather than direct cytotoxicity was the 
primary mechanism used by CTLs to control the tumor. In contrast, Breart et al.(18) used 
intravital two-photon imaging to show that apoptotic events almost exclusively occurred when 
tumor cells were contacted by T cells, thus arguing for a major role of direct cytotoxicity. 
Moreover, they generated mixed tumors, comprising both Ova-expressing EG7 cells and non-
Ova-expressing EL4 cells. In these mixed tumors only the antigen expressing EG7 cells were 
eliminated, arguing against an indiscriminate effect from IFNγ. We integrate the data acquired at 
various levels into both an ordinary differential equation (ODE) model, and a spatial agent-
based model (ABM). Applying these models to the in vivo data we show that the observed T cell 
densities and slow killing rate were insufficient to explain the population-level tumor regression 
observed in the mice. We found that an antiproliferative effect mediated through IFNγ signalling 
allowed CTLs to influence far more cells than direct killing alone, therefore leading to a 
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substantially greater impact on tumor progression. Our modelled scenario corroborated the 
notion that IFNγ plays a crucial role in EL4 tumor control, and reconciles this with the apparently 




Since the main aim of this work is to test whether CTLs could have controlled the tumor through 
the sole means of direct killing, we favoured ‘optimism’ from the CTL viewpoint wherever the in 
vivo dataset was ambiguous. Thus, we chose model assumptions that promoted tumor control 
through direct CTL killing.  
 
Tumor Cells. Tumor volume measurements in the absence of CTL transfer were used to fit the 
growth rate of both our ODE model and ABM. Based on manual counting of the images, we 
estimated that the density of tumor cells was approximately 106 cells mm-3. This value is the 
default used in all our models. Moreover, Breart et al.(18) used flow cytometry to estimate the 
absolute number of tumor cells inside two tumors 10 days after inception (in the absence of 
infused T cells). An average of 4 x 106 cells were recovered, at a time-point where the average 
tumor volume was ~17mm3, corresponding to a density of approximately 0.25 x 106 cells mm-3. 
Given that a substantial fraction of tumor cells were likely lost during the cell isolation 
procedure(31), this can be viewed as an absolute underestimate of the tumor cell density. To 
convert between tumor volume and number of tumor cells, we consider direct proportionality 
between these quantities.  
 
Dead tumor cells are not recognised by CTLs in our models yet are not immediately removed 
from the models. Parnaik et al. (32) found that cultured rat cerebellar neurons were completely 
cleared within 3 hours of apoptosis by professionally phagocytic microglia, whereas the same 
cells were incompletely cleared after 9 hours by non-professionally phagocytic epithelial cells. 
We therefore considered tumor cells to persist for an average of 6 hours after apoptosis. 
Because the number of CTLs in our modelled tumors is proportional to the tumor volume (the 
sum of numbers of dead and alive cells), inclusion of dead tumor cells increases the ratio of 
effector : alive target (E:T ratio) and thereby increases the total killing rate.  
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CTLs. Breart et al.(18) transferred CTLs to mice on day 5 after tumor injection. Before this point 
we consider CTLs to be absent from the tumor. Because killing undertaken by any endogenous 
CTL should also occur in the control tumors where no CTLs were transferred, this is already 
accounted for in our fit to the tumor growth data in the absence of CTLs.  Breart et al.(18) 
measured the density of CTLs within the tumor on days 7 (12500 CTLs mm-3) and 8 (25000 
CTLs mm-3). Based on our estimate of 106 tumor cells mm-3, this corresponds to an 
Effector:Target ratio of 1:80 on day 7, and 1:40 on day 8. Due to the temporally sparse 
measurements the exact dynamics of T cell infiltration into the tumor are not known and for 
simplicity we linearly interpolated between the available data points. Beyond day 8, further data 
on the density of infiltrating CTLs was not recorded. In reality T cell numbers likely peak and 
then decline a few days after adoptive transfer(22), and T cells often suffer from exhaustion 
after extended time in the tumor(33,34). However, it is certainly possible that CTL numbers 
continued to increase beyond day 8. In line with our policy of taking the most optimistic 
assumptions from the CTL viewpoint, we considered the ratio of effector T cells to total tumor 
cells (Effector:Tumor-Cell ratio) to continue to linearly increase after day 8. Also in line with our 
policy, we do not consider CTLs to diminish in effector function over time (which would make it 




Model setup. ODE simulations were performed in the R language, using the package ‘deSolve 
1.14’. Models were fitted using the Levenberg Marquardt algorithm in the package ‘minpack.lm 
1.2-1’. Our ODE model was designed to test whether CTLs could control tumors with the 
observed direct killing rate of k = 4 kills CTL-1 day-1. Therefore, we deliberately simplified the 
model, with assumptions chosen to maximise the likelihood of tumor control. The model 





= 𝑔𝑇 − 𝑘𝐸(𝑡) , (1) 
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= 𝑘𝐸(𝑡)  −  𝑑𝐷, (2) 
 
 
Thus, tumor cells T are considered to grow exponentially with rate g (day-1) in the absence of 
CTLs, because the experimental tumors clearly did not yet suffer from competition for resources 
during the measurement interval (Fig. 1A). Tumor cells are killed at rate k (CTL-1 day-1) by a 
population of effector cells E(t), where E(t) is determined based on the number of dead and 
alive tumor cells (Data Interpretation, Fig. 1B): 
E(𝑡) = λ(𝑇 + 𝐷) {
0                                                  𝑖𝑓 (𝑡 ≤ 5)
(𝑡 − 5)                              𝑖𝑓 (5 < 𝑡 ≤ 7)
2(1 + (𝑡 − 7))                        𝑖𝑓 (7 < 𝑡),
 
 




which defines the rate of increase in the Effector:Tumor-Cell ratio 𝐸: (𝑇 + 𝐷). 
(3) 
 
Killed cells D are cleared at rate d (day-1). We took the killing rate to be proportional to the 
number of CTLs and independent of the number of target cells, implying that CTLs are 
considered to always kill at their maximal rate. In reality a dual saturation function, with 
saturation in both effector and tumor cell number T, is a more complete description of CTL 
killing (Supplementary Methods) (35,36). However, we aimed to model a situation that favours 
CTL control of the tumor. In such a best-case scenario from the CTL viewpoint, CTLs always 
have sufficient targets to kill and need never search for targets. As such our simplified ODE 
model is an extremely optimistic scenario from the point of view of the CTLs. This simplification 
implies that our model is a good approximation as long as the E:T ratio remains sufficiently low.  
ABM 
 
Model setup. ABM simulations were implemented in C++14, using boost 1.69.0. Visualisations 
were rendered in C++ using VTK 8.0. We use an asynchronously updating ABM to simulate 
tumor growth, T cell infiltration and migration, and tumor regression. Our ABM features two 
types of agents: CTLs and tumor cells. Tumor cells live on a regular 3D lattice where each cell 
occupies a single lattice site; tumor cells do not share sites with each other. Empty sites in the 
lattice represent extracellular matrix, or other cell types not interfering with the tumor.  Lattice 
on May 29, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 30, 2019; DOI: 10.1158/0008-5472.CAN-18-3147 
7 
sites have length 10μm by default, roughly corresponding to our default tumor cell density 
assumptions. Each tumor cell grid point contains information on the tumor cell type (either EG7 
or EL4), the amount of damage it has sustained from CTL attacks, and whether it is alive or not. 
Throughout the simulation we track the displacement of the furthest tumor cell from the centre of 
the lattice; this measurement is used to dynamically adjust the size of the simulation domain. 
The domain is a sphere, extending from the lattice centre out to a radius 5 lattice sites (50μm) 
beyond the displacement of the furthest tumor cell. 
 
Tumor cell behaviour. The tumor is initialised on day 0, by filling T0 lattice sites with tumor 
cells within a radius of Ri from the lattice centre. The simulation is advanced in timesteps of 1 
minute (Δt). At each timestep each tumor cell is liable to to replicate with probability gΔt. Cells 
replicate into a random neighbouring square if one is available. We implemented short range 
dispersal (similar to (37)) as a computationally inexpensive means to achieve exponential, 
spheroidal tumor growth whilst comfortably allowing simulation of over 108 individual agents. 
Candidate dividing cells whose surroundings are fully occupied attempt to disperse from the 
tumor with probability pdisp. Dispersing cells produce a daughter cell for which a new location is 
chosen based on a random walk with mean dispersal distance proportional to the current tumor 
radius. If the chosen site is vacant the daughter cell occupies this site, otherwise the dispersal 
attempt fails.   
  
CTL infiltration. CTLs are associated with a location corresponding to a grid site, however they 
are not explicitly represented on the grid and as such can share space with other CTLs or tumor 
cells. Thus, CTLs do not contribute to the tumor mass and are able to move through tumor 
tissue, attempting to form conjugates with antigen expressing tumor cells. We allowed for such 
co-occupancy because CTLs can easily move in between other cells in densely packed 
environments such as a lymph node(38) or the skin epidermis(39), and are able to cooperate to 
kill individual targets(19). Because of the relatively low Effector:Tumor-Cell ratios observed in 
the experimental data, in practise our CTLs rarely share lattice sites. Specifically, two or more 
CTLs share a lattice site only ~2% of the time, and 3 or more share a site ~0.01% of the time on 
day 8 of a typical simulation. Following the experimental setup, CTLs infiltrate the tumor on day 
5 after tumor inception. New CTLs arrive at random points within the existing simulation domain. 
At each timestep a target number of CTLs is calculated based on the Effector:Tumor-Cell ratio 
we estimated from the data (in equivalence with the ODE model). If the number of CTLs inside 
the simulation is below the current target, new CTLs are added to the simulation until the target 
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is reached. CTLs are only removed from the simulation when they migrate outside the 
simulation domain. The number of CTLs may therefore exceed the target density, albeit only 
whilst the tumor disappears more quickly than CTLs migrate out of the simulation domain. 
 
CTL migration. CTLs migrate until they reach a site occupied by a tumor cell; CTLs that 
migrate outside the simulation domain are removed. Whilst a CTL is migrating, each time-step it 
randomly moves to an adjacent lattice site within its 3D Moore neighbourhood including its 
current location. Thus, there is a 1/27 probability of no movement, a 6/27 probability of a 10 μm 
movement, 8/27 probability of a10√2μm movement, and a 8/27 probability of a 10√3μm 
movement. Therefore, the resulting migration speed is 11.5μm per minute, which is in close 
agreement with previously measured values in the EL4/EG7 tumor (29). CTLs that find tumor 
cells arrest with probability parr, and subsequently attack tumor cells with probability phit or 
detach and resume migration with probability pdet.. By default  parr = 1 and  pdet = 0, although 
these are varied to parr = 0.9 and  pdet = 0.01 in the simulations where we examine multi hitting 
CTL. CTLs are immediately released from conjugates if the target cell dies. 
 
Effects of CTLs on tumor cells.  Tumor cells may sustain nhit hits from CTLS before apoptosis 
occurs. By default nhit = 1, in which case CTLs attack targets with an attack rate identical to the 
killing rate. In simulations where multiple hits are required for tumor cell death the base attack 
rate is multiplied by the number of hits required for apoptosis. Therefore the overall killing 
potential of the CTLs is controlled between single-hit and multiple-hit simulations to obtain equal 
killing rates. 
 
In simulations with IFNγ, that cytokine is produced at a constant rate by CTLs whilst conjugated 
with tumor cells. IFNγ is consumed by tumor cells, and tumor cells cannot divide when the local 
IFNγ concentration exceeds a threshold value. We set the diffusion parameters such that the 
threshold occurs at around 3 cell lengths away from a conjugated CTL. For details see the 
Supplementary Methods. 
 
Mixed tumors. We simulated mixed EL4/EG7 tumors by seeding a 50/50 mixture of cells on 
day 0. The only difference between these cell types is that EG7 cells are not recognised by 
CTLs. 
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Results 
Direct CTL cytotoxicity is not sufficient to mediate in vivo regression of EG7 
tumors 
 
In the in vivo data of Breart et al.(18), transferred OTI effector T cells rapidly controlled an 
infused EG7 tumor, following direct contact with tumor cells. However, each infiltrating CTL 
killed on average only 4 tumor cells per day and it is unclear if tumor regression should be 
expected based on the density and cytotoxic activity observed in this in vivo data. To test 
whether CTLs could reasonably be expected to control the in vivo tumors, we employed an 
ODE model (see Methods) that integrated the measurements made at various levels. Instead of 
providing a detailed description of the tumor and its interactions with the immune system, the 
goal of this model was rather to assess the possibility that direct killing could have solely 
accounted for tumor regression. The simplifications that we made in the ODE model always 
favoured the CTLs, i.e., they made tumor regression more likely. If indeed CTLs were capable 
of controlling the tumor by direct killing alone, tumor regression would certainly be observed in 
this simplified model. 
 
Modelling tumor growth as an exponential process resulted in a good match to the tumor 
measurements from Breart et al.(18) for the case without T cell transfer (Fig. 1A), suggesting 
that tumor growth was not yet inhibited by factors such as competition for nutrients. 
Subsequently, we introduced a population of CTLs into this model, with Effector:Tumor-Cell 
ratio based also upon experimental measurements (Fig. 1B).  The impact on the tumor was 
limited when CTLs killed tumor cells at a rate of k=4 CTL-1day-1 as reported by Breart et al.(18) 
(Fig. 1C), despite the continuous increase in intratumoral T cell numbers (Fig. 1D). The killing 
rate measurements were relatively uncertain compared to the other parameters in the ODE 
model, perhaps having varied over time or throughout the tumor. To address that uncertainty,we 
simulated CTL populations killing with rate up to k=16 CTL-1day-1, which is at the high end of the 
range of reported estimates for CTL killing performance in vivo (40). As a side note, in this 
model such a 4-fold increase of the killing rate is equivalent to a 4-fold increase of the CTL 
infiltration rate. With k=16 our simulated tumors were controlled, although this control occurred 
only at much later time points than was the case for the in vivo tumors. Thus, even for the 
extremely optimistic scenario we consider and using a substantially higher killing rate than was 
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measured experimentally, direct CTL lysis alone could not explain the observed in vivo tumor 
regression. 
Agent Based Model supports notion that CTL cytotoxicity is insufficient to 
mediate in vivo regression of EG7 tumors 
 
We developed a spatially explicit ABM with tumor cells and CTLs as agents to contrast against 
the idealised ODE model (Fig. 2A-B).  As in the ODE model, in the ABM the overall growth rate 
of the tumor was matched to the data in the absence of CTLs (Fig. 2C), although the ABM 
differs in that tumor cells cannot divide when fully surrounded, i.e., there is competition for 
space (video S1). Tumors were much less well controlled in the ABM than they were in the ODE 
model (Fig. 2D); even at a killing rate of k=16 CTL-1day-1 the tumor was not controlled in the 
ABM. There are two reasons for this discrepancy. Firstly, when compared to the ODE model, 
the ABM has the added requirement that CTLs must migrate in order to find tumor cells to kill. 
Indeed, the fraction of CTLs in conjugates was lower in simulations with k=16 CTL-1day-1 than in 
those with k=4 CTL-1day-1(Fig. 2E), because faster killing CTLs spend less time conjugated with 
tumor cells. The second source of discrepancy between the ODE and ABM results stems from 
the competition for space between tumor cells that occurs in our ABM; CTL killing eases such 
competition, so tumor control is more difficult. Thus, the idealised ABM highlights that CTLs 
might make their own job more difficult by being highly efficient killers. Overall, the ABM 
simulations confirm that CTL-mediated direct killing alone cannot explain EG7 tumor regression. 
 
IFNy-mediated cell cycle arrest is sufficient for tumor control  
 
Because IFNγ has been widely implicated in tumor eradication (20,21,23–25,41), we added 
production and diffusion of this cytokine to our ABM. We focussed on an antiproliferative effect 
of IFNγ because Breart et al.(18) only detected apoptosis in tumor cells directly contacted by 
CTLs, an observation which is inconsistent with the notion of significant IFNγ cytotoxicity 
towards EG7 cells. To test the contribution of the putative antiproliferative effect of IFNγ, we 
simulated tumors with k=4 CTL-1day-1 or k=16 CTL-1day-1, in the presence or absence of IFNγ. 
In our simulated tumors, the antiproliferative effect of IFNγ was much stronger than the contact 
dependent CTL lysis, even with k=16 CTL-1day-1 (Fig. 3A). Although tumors were rapidly 
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controlled in our model with IFNγ, they were not entirely eradicated. This can be explained by 
the low number of CTLs in the IFNγ simulations (Fig. 3B), together with the fraction of 
conjugated CTLs which drops after the onset of tumor regression for k=16 CTL-1day-1 (Fig. 3C). 
CTLs mostly eradicate tumor cells in the centre of the spheroid, but some pockets of tumor cells 
in the periphery survive and allow the tumor to escape (Fig. 3D, Video S2). These modelled 
behaviours are consistent with literature observations that solid tumors “melt from the inside” 
(42), and that EL4 tumors may rebound after an initial response to transferred CTLs (43). In 
summary, tumor cell cycle arrest due to cytokine production by CTLs in addition to their 
cytotoxicity can explain the observed response of EG7 cells to a population of transferred CTLs. 
 
CTL cooperativity leads to heterogeneity in killing rate 
 
Our ABM predicted an almost negligible role for direct killing in tumor regression, with or without 
the presence of IFNγ. However, the CTL killing rate may in reality have been higher than the 
measured k=4 CTL-1day-1 and may not have been constant over time (36). Factors that could 
play a role here include the ability of CTLs to kill collaboratively (19)  and that of cancer cells to 
resist multiple CTL ‘hits’ before apoptosis is triggered (44). We therefore used our ABM to 
assess whether the measurement of k=4 CTL-1day-1 could have resulted from a higher ‘intrinsic’ 
CTL killing rate. We compared simulations in which tumor cells die after a single ‘lethal hit’ with 
simulations where an accumulation of several hits was required for apoptosis. There was no 
substantive difference between the single hit and multi hit scenarios in terms of tumor growth 
(Fig. 4A), or number of CTLs (Fig. 4B). At early time points, the fraction of CTLs in conjugates in 
the multi hit model was slightly higher than in the single hit model (Fig. 4C) and the temporal 
pattern of killing rate per simulated CTL (Fig. 4D) or per conjugated CTL (Fig. 4E) differs 
between the two settings. Multi hitting CTL populations initially killed at a low rate, because 
targets had generally not acquired enough damage to die. Subsequently, targets accumulated 
damage and the manifested killing rate per conjugated CTL rose above the killing rate for the 
single hit scenario (Fig. 4E). Similar to the killing rate-measurement procedure of Breart et al. 
(18), we measured killing in 100𝝻m x 100𝝻m x 30𝝻m ‘windows’ for a two hour period at the 
beginning of day 8 during a cumulative total of 75 hours of conjugated CTL imaging time(18). 
Our analysis shows that such sample sizes in general reflect the global killing rate well (Fig. 4F). 
As a side note, in our model the infiltration of the tumors by CTLs was relatively homogeneous, 
meaning that damage to targets occurred roughly evenly throughout the tumor (Fig. 4G). 
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Although heterogeneous infiltration may lead to strong spatial variability in killing rate, we 
conclude that temporal variation in killing is likely large, especially when CTLs cooperate.  
 
Direct killing plus antiproliferative IFNγ accounts for selective elimination of 
antigen positive cells 
 
Breart et al.(18) noted that in mixed EL4/EG7 tumors, the non-cognate antigen expressing 
tumor cells (EL4) grew more or less unconstrained and it is unclear whether the antiproliferative 
effect of IFNγ is consistent with this finding. We therefore simulated mixed tumors, containing 
patches of antigen positive EG7 cells or antigen negative EL4 cells. EL4 cells were considered 
not to be recognized and thus not affected by direct interactions with CTLs, but could be 
affected by IFNγ that diffused from nearby locations. When initialised with a 50% mixture of 
EL4/EG7 cells, our simulated tumors form patches with similar spatial dimensions to the images 
from Breart et. al. (Fig. 5A). We simulated the transfer of CTLs into the mixed tumor model, 
upon which CTLs preferentially accumulated in regions of Ova-expressing EG7 cells where they 
began killing these cells and secreting IFNγ (Fig. 5B,Video S3). IFNγ concentrations were 
generally higher in regions of EG7 cells compared to regions of EL4 cells, yet despite the limited 
(~30 μm) range of IFNγ diffusion in our model many EL4 cells were prevented from replicating 
for a period of approximately 2 days, when the activity of the CTLs was greatest (Fig. 5C). By 
day 10 most EG7 cells were eliminated, and the CTLs, being deprived of stimulation, stopped 
producing IFNγ. After this point EL4 cells resumed growth, eventually filling the spaces left 
behind by the dead EG7 cells. EL4 cells were thus not so much affected by the presence of the 
CTLs. In conclusion, local production of anti-proliferative IFNγ is consistent with the 
experimental observation that within mixed tumors primarily cognate-antigen expressing cells 




Immunotherapies involving CTLs are able to mediate regression or tumor control in cancers that 
were previously out of reach for conventional treatments. Despite major progress, many patients 
fail to respond, and the mechanistic insight required to explain this disparity in outcomes is 
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lacking. Lysis of infected or malignant cells following direct physical contact is the canonical CTL 
effector function, but indirect effects of CTLs such as production of cytokines are increasingly 
recognised as having an important role in CTL mediated tumor regression(21,22,25,45). The 
relative importance of these different mechanisms remains unclear and is likely to depend on 
characteristics of both the tumor and the T cells involved. Here we developed an ABM and an 
ODE model of tumor regression following adoptive transfer of a population of CTLs attacking 
EL4/EG7 tumor cells. Using these models, we attempted to quantify the relative contribution of 
direct CTL killing towards tumor regression in the EL4/EG7 model. Our simulated tumors were 
not controlled by direct CTL killing only, so we conclude that direct killing was not a sufficient 
explanation for regression in the EL4 tumor model.   
 
In our ABM we also included simulation of an antiproliferative effect of IFNγ, because 
Hollenbaugh et. al.(21) observed that IFNγ deficient T cells display substantially reduced tumor 
controlling abilities. We modelled an antiproliferative effect because the tumor cells were only 
observed to die after CTL contact, evidence against a substantial long distance cytotoxic effect 
of IFNγ in this in vivo setting. IFNγ secreted by CTLs has been shown to contribute to 
regression in a different tumor model(22), by arresting the cell cycle of tumor cells. Although 
IFNγ has no direct antiproliferative effect on EL4 cells in vitro(22) it has been shown that nitric 
oxide (NO) is secreted by stromal cells after exposure to IFNγ(21). Such NO reduces 
proliferation of EL4 cells in vitro(21), and thereby provides a possible mechanism for the growth 
inhibition included in our model. Note that we incorporated a direct effect of IFNγ on tumor 
proliferation rather than explicitly including this potential cascade of events, because detailed 
quantitative measurements on these mechanisms are currently lacking.  
 
Although the antiproliferative effect of IFNγ may be an important contributor to tumor control, 
IFNγ may have had other effects which we did not take into account. First, although we were 
able to explain regression without a substantial cytotoxic effect of IFNγ, we cannot exclude that 
possibility. Since such an effect does not act specifically towards tumor cells presenting cognate 
antigen it may be an important mechanism to control antigen loss variants, which might 
otherwise allow tumors to recur.  Second, IFNγ may induce immuno-tolerance leading to 
decreased CTL effector function(46). Third, it has been speculated that IFNγ aids in control of 
tumors by recruitment of innate effector cells(24), or destruction of tumor vasculature(45). Our 
model included neither of these effects because they were not apparent in the experiments we 
based our model on. However, it is possible that these events happened at a later time, after 
on May 29, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 30, 2019; DOI: 10.1158/0008-5472.CAN-18-3147 
14 
observations of CTL killing were made. This further underlines that measurements are required 
throughout the entire course of tumor rejection, in order to gain a full understanding of the 
sequence of events that occurs. 
 
Apart from the role that IFNγ may play in tumor control, our modeling has also highlighted a 
potential explanation for temporal variation in measured killing rates of CTLs. Tumor cells may 
be able to endure multiple attacks from CTLs before apoptosis is triggered(19,44), When we 
implemented such variability in our model, we indeed found an increase in killing rate over the 
course of tumor regression. This dependence of killing rate upon measurement time is in 
agreement with our previous modelling work(36) on T cell-target cell interactions.  
 
A criticism of our approach could be that our simulations do not capture all the myriad complex 
interactions within the tumor microenvironment. Indeed, our models are a highly idealised 
representation of reality, since they contain only the mechanisms we explicitly chose to include. 
This would likely be a problem if using the model as a fully predictive tool for other settings, 
since the model predictions will not be valid in tumors where unincluded mechanisms are 
important. However, when applying the model as a diagnostic tool (as we have here), model 
simplicity is a major advantage. This approach allowed us to quantitatively test whether 
observations made at the cellular level could explain emergent behaviour of the tumor as a 
whole, without the interference of confounding variables.  
 
Our work highlights the need for further investigation of indirect effects mediated by CTLs in an 
anti-tumor immune response. Although many mechanisms utilised by CTLs to control tumors 
have been identified, quantitative measurements detailing their contribution to regression are 
scarce. Such quantitative understanding would enable a more sophisticated and systems based 
understanding of the interplay of various mechanisms in tumor regression following 
immunotherapy - and likely enable better targeted interventions. Future studies should therefore 
aim to characterise the potential contribution of various mechanisms to tumor regression. 
Computational models that integrate in vitro and in vivo experiments, such as those developed 
here and as developed by others(47–49), can be a valuable tool to aid in this process.   
 
on May 29, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 30, 2019; DOI: 10.1158/0008-5472.CAN-18-3147 
15 
Acknowledgements 
We would like to thank Beatrice Bréart and Philippe Bousso for providing their previously 
published data and for useful feedback on our modeling of their data. This work is supported by 






1.  Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. Analysis of Drug Development 
Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res. 2018;24:1785–94. 
2.  Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. Nat Rev 
Drug Discov. 2018;17:161–2. 
3.  Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. 
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor 
infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646–
55. 
4.  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable 
complete responses in heavily pretreated patients with metastatic melanoma using T-cell 
transfer immunotherapy. Clin Cancer Res. 2011;17:4550–7. 
5.  Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, et al. 
Treatment of metastatic uveal melanoma with adoptive transfer of tumor-infiltrating 
lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 
2017;18:792–802. 
6.  Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T 
cells for the immunotherapy of patients with EGFR-expressing advanced 
relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59:468–79. 
7.  Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-
term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. 
Blood. 2011;118:6050–6. 
8.  Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human 
Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified 
T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015;33:1688–96. 
9.  Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined 
Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 
2015;373:23–34. 
on May 29, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 30, 2019; DOI: 10.1158/0008-5472.CAN-18-3147 
16 
10.  Swart M, Verbrugge I, Beltman JB. Combination Approaches with Immune-Checkpoint 
Blockade in Cancer Therapy. Front Oncol. 2016;6:233. 
11.  Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. 
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. 
Immunity. 2016;44:343–54. 
12.  Weichselbaum RR, Liang H, Deng L, Fu Y-X. Radiotherapy and immunotherapy: a 
beneficial liaison? Nat Rev Clin Oncol. 2017;14:365–79. 
13.  Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T 
lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and 
secretion of lytic proteins via a non-granule pathway. Eur J Immunol. 1995;25:1071–9. 
14.  Wiedemann A, Depoil D, Faroudi M, Valitutti S. Cytotoxic T lymphocytes kill multiple targets 
simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc Natl 
Acad Sci U S A. 2006;103:10985–90. 
15.  Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated 
by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 
1994;369:31–7. 
16.  Smyth MJ, Kershaw MH, Darcy PK, Trapani JA. Adoptive transfer: the role of perforin in 
mouse cytotoxic T lymphocyte rejection of human tumor xenografts in vivo. 
Xenotransplantation. 1998;5:146–53. 
17.  Caldwell SA, Ryan MH, McDuffie E, Abrams SI. The Fas/Fas ligand pathway is important 
for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of 
experimental CMS4 lung metastases. J Immunol. 2003;171:2402–12. 
18.  Breart B, Lemaître F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell 
cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest. 2008;118:1390–7. 
19.  Halle S, Keyser KA, Stahl FR, Busche A, Marquardt A, Zheng X, et al. In Vivo Killing 
Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell 
Cooperativity. Immunity. 2016;44:233–45. 
20.  Barth RJ Jr, Mulé JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis 
factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating 
lymphocytes. J Exp Med. 1991;173:647–58. 
21.  Hollenbaugh JA, Dutton RW. IFN-γ Regulates Donor CD8 T Cell Expansion, Migration, and 
Leads to Apoptosis of Cells of a Solid Tumor. The Journal of Immunology. American 
Association of Immunologists; 2006;177:3004–11. 
22.  Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, et al. Cytotoxic T 
lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest. 
Cancer Immunol Res. 2015;3:26–36. 
23.  Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, et al. IFN-
gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy 
approach. Mol Ther. 2003;7:185–92. 
on May 29, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 30, 2019; DOI: 10.1158/0008-5472.CAN-18-3147 
17 
24.  Nagoshi M, Sadanaga N, Joo HG, Goedegebuure PS, Eberlein TJ. Tumor-specific cytokine 
release by donor T cells induces an effective host anti-tumor response through recruitment 
of host naive antigen presenting cells. Int J Cancer. 1999;80:308–14. 
25.  Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, 
et al. Tumor rejection by local interferon gamma induction in established tumors is 
associated with blood vessel destruction and necrosis. Int J Cancer. 2011;128:371–8. 
26.  Nguyen HH, Kim T, Song SY, Park S, Cho HH, Jung S-H, et al. Naïve CD8(+) T cell 
derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β 
immunosuppression in the tumor microenvironment. Sci Rep. 2016;6:28208. 
27.  Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, et al. Non-
redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across 
tumor vascular checkpoints. Nat Commun. 2015;6:7458. 
28.  Yao Y, Chen S, Cao M, Fan X, Yang T, Huang Y, et al. Antigen-specific CD8+ T cell 
feedback activates NLRP3 inflammasome in antigen-presenting cells through perforin. Nat 
Commun. 2017;8:15402. 
29.  Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of 
cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med. 2007;204:345–56. 
30.  Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW. The rate of the CD8-dependent 
initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or 
TNF-mediated cytolysis. J Immunol. 2004;173:1738–43. 
31.  Steinert EM, Schenkel JM, Fraser KA, Beura LK, Manlove LS, Igyártó BZ, et al. Quantifying 
Memory CD8 T Cells Reveals Regionalization of Immunosurveillance. Cell. 2015;161:737–
49. 
32.  Parnaik R, Raff MC, Scholes J. Differences between the clearance of apoptotic cells by 
professional and non-professional phagocytes. Curr Biol. 2000;10:857–60. 
33.  Hirano K, Hosoi A, Matsushita H, Iino T, Ueha S, Matsushima K, et al. The nitric oxide 
radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-
derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T 
lymphocyte immunotherapy. Oncoimmunology. 2015;4:e1019195. 
34.  Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends 
Immunol. 2015;36:265–76. 
35.  Gadhamsetty S, Marée AFM, Beltman JB, de Boer RJ. A general functional response of 
cytotoxic T lymphocyte-mediated killing of target cells. Biophys J. 2014;106:1780–91. 
36.  Gadhamsetty S, Marée AFM, Beltman JB, de Boer RJ. A Sigmoid Functional Response 
Emerges When Cytotoxic T Lymphocytes Start Killing Fresh Target Cells. Biophys J. 
2017;112:1221–35. 
37.  Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model 
predicts that dispersal and cell turnover limit intratumor heterogeneity. Nature. 
2015;525:261–4. 
on May 29, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 30, 2019; DOI: 10.1158/0008-5472.CAN-18-3147 
18 
38.  Beltman JB, Marée AFM, Lynch JN, Miller MJ, de Boer RJ. Lymph node topology dictates T 
cell migration behavior. J Exp Med. 2007;204:771–80. 
39.  Ariotti S, Beltman JB, Chodaczek G, Hoekstra ME, van Beek AE, Gomez-Eerland R, et al. 
Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize 
local antigen. Proc Natl Acad Sci U S A. 2012;109:19739–44. 
40.  Halle S, Halle O, Förster R. Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity In 
Vivo. Trends Immunol. 2017;38:432–43. 
41.  Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N. Cytotoxic T lymphocytes block tumor 
growth both by lytic activity and IFNγ-dependent cell-cycle arrest. Cancer Immunol. Res. 3, 
26–36. doi: 10.1158/2326 …. CIR-14-0098; 2015; 
42.  Blohm U, Potthoff D, van der Kogel AJ, Pircher H. Solid tumors “melt” from the inside after 
successful CD8 T cell attack. Eur J Immunol. 2006;36:468–77. 
43.  Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor 
evasion of immune surveillance. Cancer Cell. 2005;8:369–80. 
44.  Caramalho I, Faroudi M, Padovan E, Müller S, Valitutti S. Visualizing CTL/melanoma cell 
interactions: multiple hits must be delivered for tumor cell annihilation. J Cell Mol Med. 
2009;13:3834–46. 
45.  Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, et al. Longitudinal confocal 
microscopy imaging of solid tumor destruction following adoptive T cell transfer. 
Oncoimmunology. 2013;2:e26677. 
46.  Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor Interferon 
Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. 
Cell. 2016;167:1540–54.e12. 
47.  Gong C, Milberg O, Wang B, Vicini P, Narwal R, Roskos L, et al. A computational 
multiscale agent-based model for simulating spatio-temporal tumor immune response to 
PD1 and PDL1 inhibition. J R Soc Interface [Internet]. 2017;14. Available from: 
http://dx.doi.org/10.1098/rsif.2017.0320 
48.  Byrne HM. Dissecting cancer through mathematics: from the cell to the animal model. Nat 
Rev Cancer. 2010;10:221–30. 
49.  Kather JN, Poleszczuk J, Suarez-Carmona M, Krisam J, Charoentong P, Valous NA, et al. 
In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal 





on May 29, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 30, 2019; DOI: 10.1158/0008-5472.CAN-18-3147 
19 
Table 1: Overview of parameters used in models, what they represent, and their default value. 
Parameters apply to ABM and ODE model unless indicated otherwise. Parameter values are 
based on data in Breart et al.(18) unless indicated otherwise. 
Parameter Description Default value 




E0 Number of CTLs at time 0 0 
D0 Number of killed tumor cells 
at time 0 
0 
k CTL killing rate 4 kills CTL-1 day-1 
g Tumor growth rate 0.86 day-1 (ODE) 
1.97 day-1 (ABM) 
da Disappearance rate of killed 
tumor cells 
2 day-1 
parr Probability of conjugate 
formation 
1 (ABM) 
nhitb Number of hits before tumor 
cell apoptosis 
1  (ABM)  
pdet Probability of conjugate 
splitting 
0 (ABM) 
pdisp Probability of tumor cell 
dispersal 
0.03 (ABM) 
Ri Initial tumor radius 120μm (ABM) 
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Figure 1. ODE model suggests direct T cell cytotoxicity is insufficient for control of EG7  
tumors. A) Tumor growth is described as exponential growth (g=0.86 day-1). B) 
Effector:Tumor-Cell ratio in the ODE model is estimated by linear interpolation of 
measured data points. After day 8, we assume a linear increase in CTL density. Arrows 
in B-D indicate time of CTL transfer. C) ODE simulation of tumor dynamics in the 
presence of actively killing CTLs, with two different killing rates. Lines represent model 
fits and dots represent experimental data. D) Total number of CTLs in simulations with 
killing.  
Figure 2. ABM confirms that direct T cell cytotoxicity is insufficient for control of EG7 
tumors. A-B) ABM tumor infiltrated by CTLs on day 7. EG7 with free adjacent lattice 
sites can proliferate (EG7p). EG7 with no free adjacent lattice sites are non-proliferating 
(EG7n.p), although they may still disperse (see Methods). C-D) Comparison of tumor 
evolution in ABM (solid lines) and ODE model (dashed lines) without (C) and with (D) 
transferred CTLs, where arrow indicates time of CTL transfer. E) Fraction of CTLs in a 
conjugate with a tumor cell throughout ABM simulations.   
 
Figure 3. Antiproliferative IFNγ leads to tumor control. A) Simulated tumor volume 
compared with and without IFNγ producing CTLs. B) Total CTL numbers in simulations 
with or without IFNγ. C) Fraction of CTLs in conjugates in simulations with and without 
IFNγ. D) Tumor on day 8, in the presence of IFNγ. 
 
Figure 4. T cell cooperativity causes heterogeneity in killing rate. A-E) Comparison of 
(A) simulated tumor volume, (B)  total number of CTLs, (C) fraction of conjugated CTLs, 
(D) killing rate per simulated CTL and (E) killing rate per conjugated CTL between 
simulations where CTLs required 1 or 5 hits to kill targets, in the presence of IFNγ. 
Arrow in A indicates CTL transfer. F) Killing rate measured from 2-hour windows 
beginning on day 8. G) Distribution of dead (EG7d), damaged (‘hit’, EG7h), or healthy 
(‘unhit’,EG7u) tumor cells.  
  
Figure 5. Antiproliferative IFNγ explains selective destruction of EG7 cells within 
EG7/EL4 mixed tumors. A) Example 2D slice from the centre of a simulated mixed 
tumor 8 days after tumor inception. B) Images showing examples of tumor composition 
(T cells in red, EG7 cells in yellow, EL4 cells in blue and IFNγ concentrations in purple) 
on day 8 during the course of EG7 regression. C) Evolution of the total volume of EG7 
or EL4 cells in mixed tumor simulations. Arrow indicates time of CTL transfer.  
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